Actively Recruiting
Study to Discover and Evaluate New Blood Biomarkers and Ultrasound Methods for Assessing Liver Fibrosis in Adults with Non-Alcoholic Fatty Liver Disease
Led by Roche Diagnostics GmbH · Updated on 2026-05-27
575
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating novel blood-based biomarkers to help diagnose and assess the stage of liver fibrosis in patients with non-alcoholic fatty liver disease NAFLD and non-alcoholic steatohepatitis NASH. These conditions can lead to serious liver problems including cirrhosis, liver failure, and liver cancer. The study also explores quantitative ultrasound combined with artificial intelligence to improve fibrosis assessment, aiming to find less invasive and more accurate diagnostic methods than liver biopsy. Participants will be recruited either when they are scheduled for a routine liver biopsy or recalled if they had a biopsy within the last 6 months and meet specific criteria. Blood samples and ultrasound scans will be collected to analyze potential biomarkers. The study is observational and involves no investigational drugs or treatments but focuses on gathering and evaluating clinical data and specimens. During the study, participants will provide blood samples and undergo ultrasound scans to assess liver fibrosis. Researchers will monitor the identification of significant and advanced fibrosis over about one year. Various biomarker panels will be evaluated for their performance in different patient groups. Participants body mass index and other health factors will be recorded to support the research, with ongoing safety and data monitoring throughout the study period.
CONDITIONS
Brief Title
Identification of Liver Fibrosis Biomarkers
Research Team
Y
Yara Pujol Lopez, Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here